ArticleEClinicalMedicine2022

Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial.

Matthias Hepprich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.